Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

- PMLiVE

Pfizer and Flagship Pioneering sign drug discovery partnership worth up to $7bn

The partners will each invest $50m upfront to develop up to ten new drug candidates

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE

Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial

The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

BeiGene signs $1.3bn deal with DualityBio for investigational solid tumour ADC

Antibody-drug conjugates are designed to target tumour cells while sparing healthy cells

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Merck reports positive phase 3 results for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

- PMLiVE

Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn

The companies will use Cullgen’s protein degradation platform to discover multiple candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links